420 pharma - Erste dosierbare Cannabis-Vaporizer in Europa

06.04.2021

Four 20 Pharma: First dosable cannabis vaporizer planned for the European market


PDF Four 20 Pharma Revolution



Four 20 Pharma cooperates with US company Ryah


First dosable cannabis vaporizers planned for the European market


Paderborn, April 06, 2021 - Four 20 Pharma GmbH is entering into a cooperation with the American manufacturer of vaporizers, RYAH Medtech, Inc. The two companies plan to jointly launch a vaporizer with cannabis flower dosing capability in the third quarter of this year. The cooperation between the two companies will introduce a new type of medication in Europe. Many cannabis patients will thus get a security in the dosage and administration of their medicine.


Founded in 2018 in New York, RYAH creates new more precise application possibilities for medical cannabis through its dosing-capable vaporizers and the networking of the collected knowledge. The device-assisted dosing capability prevents, among other things, overdosing beyond the level of symptom relief.


"Finally, there is real technological progress in terms of dosing capability. This is a revolutionary step towards acceptance for cannabis medication.


The controllable dosage form creates additional safety for patients* and medical professionals in the treatment with cannabis," explains Thomas Schatton, CEO Four 20 Pharma GmbH. The company, based in Paderborn (NRW), is known as a manufacturer of untreated medical cannabis with high quality standards.


"Our new partnership with Four 20 Pharma GmbH allows RYAH to leverage Four 20 Pharma's clinical distribution network and compliance for herbal medicine in the region," says Gregory Wagner, CEO RYAH Medtech, Inc. "The German herbal medicine market represents a significant growth opportunity and this new distribution agreement with Four 20 Pharma is an integral part of and accelerates our EU strategy," Wagner adds.


The Managing Director of Arbeitsgemeinschaft Cannabis als Medizin e.V., Dr. Franjo Grotenhermen, also welcomes the technological progress: "I am following with great interest the development of a new generation of vaporizers that allow to control the inhaled dose better and easier than before, thus giving doctors and patients more safety and furthermore improving the acceptance of a cannabis therapy."


About Four 20 Pharma GmbH


Four 20 Pharma GmbH is GDP and GMP certified as a manufacturer, wholesaler and importer of medical cannabis as well as medical devices. The company, based in Paderborn, Germany, was founded in 2018 and holds a narcotics license in accordance with Section 3 of the German Narcotics Act (BtMG) and a pharmaceutical wholesale license in accordance with Section 52a of the German Medicines Act (AMG) for all of Europe. In addition, the medical cannabis specialist holds the necessary import licenses for the importation of medical cannabis into Germany, a manufacturing permit, and the necessary, product-specific permit in accordance with § 7 AMG and § 1 AMRadV for the marketing of medicinal products. Four 20 Pharma GmbH is committed to the Association for Cannabis as Medicine (ACM) as a gold sponsor. The company supports physicians, pharmacies, medical institutions and patients as a reliable partner in the field of medical cannabis. For more information, please visit our website at www.420pharma.de.



Press contact:

Christopher Thiele
presse@pharma.eu
+49 5251 39032-10

Sticky Phone icon